Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-Intron, GM-CSF, and Thalidomide in Metastatic Renal Cell Carcinoma
NCT00090870Phase 2Terminated
- Sponsor
- Medical University of South Carolina
- Start
- Apr 2002
- Primary completion
- Mar 2010
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2b, sargramostim and thalidomide in renal cell carcinoma (RCC), sponsored by Medical University of South Carolina. Primary endpoint: Response Rate. Started Apr 2002; status: terminated.
02
Drugs
peginterferon alfa-2bsargramostimthalidomide
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00090870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090870.